ALPS Advisors’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-3,702
Closed -$368K 887
2019
Q3
$368K Sell
3,702
-769
-17% -$73.1K ﹤0.01% 568
2019
Q2
$413K Sell
4,471
-236
-5% -$22.4K ﹤0.01% 616
2019
Q1
$444K Sell
4,707
-16,953
-78% -$1.48M ﹤0.01% 557
2018
Q4
$1.39M Buy
+21,660
New +$1.6M 0.01% 255
2018
Q3
Sell
-6,769
Closed -$538K 1137
2018
Q2
$538K Sell
6,769
-2,170
-24% -$180K ﹤0.01% 535
2018
Q1
$797K Buy
8,939
+3,762
+73% +$361K 0.01% 360
2017
Q4
$540K Buy
5,177
+369
+8% +$41.6K ﹤0.01% 479
2017
Q3
$701K Sell
4,808
-353
-7% -$48.1K 0.01% 308
2017
Q2
$670K Buy
5,161
+362
+8% +$44.4K ﹤0.01% 306
2017
Q1
$597K Sell
4,799
-186
-4% -$22.3K ﹤0.01% 283
2016
Q4
$577K Sell
4,985
-445
-8% -$49.6K ﹤0.01% 296
2016
Q3
$568K Sell
5,430
-626
-10% -$67.8K ﹤0.01% 256
2016
Q2
$597K Buy
6,056
+1,700
+39% +$176K 0.01% 230
2016
Q1
$436K Buy
+4,356
New +$449K ﹤0.01% 457
2015
Q3
Sell
-4,362
Closed -$505K 845
2015
Q2
$505K Buy
4,362
+68
+2% +$7.77K ﹤0.01% 500
2015
Q1
$495K Buy
+4,294
New +$513K ﹤0.01% 591
2014
Q1
Sell
-6,552
Closed -$498K 735
2013
Q4
$498K Buy
6,552
+3,220
+97% +$255K 0.01% 382
2013
Q3
$256K Buy
+3,332
New +$234K ﹤0.01% 332

Other funds holding CELG

ALPS Advisors's CELG Position: Q4 2019 in Review

ALPS Advisors sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 3,702 shares — an estimated $368K sold.

ALPS Advisors first reported a position in CELG in Q3 2013 and held it in 18 quarters. The position peaked at $1.39M in Q4 2018. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • ALPS Advisors reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • ALPS Advisors sold 3,702 Celgene Corp shares in Q4 2019, an estimated $368K.
  • ALPS Advisors first reported a position in Celgene Corp in Q3 2013 and held it in 18 quarters.
  • ALPS Advisors's Celgene Corp position peaked at $1.39M in Q4 2018.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.